Compare PBLS & EROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBLS | EROC |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | 2026 | 2026 |
| Metric | PBLS | EROC |
|---|---|---|
| Price | $38.91 | $15.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 347.7K | ★ 2.5M |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.56 | $8.88 |
| 52 Week High | $38.83 | $17.98 |
| Indicator | PBLS | EROC |
|---|---|---|
| Relative Strength Index (RSI) | 70.43 | 64.03 |
| Support Level | $26.42 | $9.57 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.56 | 1.24 |
| MACD | 0.27 | 0.91 |
| Stochastic Oscillator | 97.71 | 84.64 |
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.